Lonnie Moulder
March 23, 2021 04:00 AM EDTUpdated 08:22 AM
Startups

Ex­clu­sive: Two M&A deals and $9B lat­er, Lon­nie Moul­der is ramp­ing up his lat­est biotech start­up. And this one comes with glob­al vi­sion built in

John Carroll

Editor & Founder

Lon­nie Moul­der may have been in silent run­ning mode in the 2 years since he closed the $5 bil­lion sale of Tesaro to Glax­o­SmithK­line …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Trump says he'll sign or­der on 'most fa­vored na­tion' drug price plans Mon­day

Lil­ly says fur­ther head-to-head tri­al da­ta back Zep­bound over No­vo’s We­govy

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

From deal to dis­as­ter: Drug­mak­ers face a changed Wash­ing­ton as Trump em­braces ‘most fa­vored na­tion’ prices

Rev­o­lu­tion’s KRAS drugs ap­pear com­pet­i­tive in sev­er­al lung can­cer set­tings

A service from the Financial Times